Found: 29
Select item for more details and to access through your institution.
Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts: Efficacy and Selection of Companion Imaging Counterpart.
- Published in:
- Pharmaceutics, 2022, v. 14, n. 8, p. 1612, doi. 10.3390/pharmaceutics14081612
- By:
- Publication type:
- Article
Preclinical Evaluation of a New Format of 68 Ga- and 111 In-Labeled Affibody Molecule Z IGF-1R:4551 for the Visualization of IGF-1R Expression in Malignant Tumors Using PET and SPECT.
- Published in:
- Pharmaceutics, 2022, v. 14, n. 7, p. N.PAG, doi. 10.3390/pharmaceutics14071475
- By:
- Publication type:
- Article
Effect of Inter-Domain Linker Composition on Biodistribution of ABD-Fused Affibody-Drug Conjugates Targeting HER2.
- Published in:
- Pharmaceutics, 2022, v. 14, n. 3, p. 522, doi. 10.3390/pharmaceutics14030522
- By:
- Publication type:
- Article
The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy.
- Published in:
- Pharmaceutics, 2021, v. 13, n. 11, p. 1974, doi. 10.3390/pharmaceutics13111974
- By:
- Publication type:
- Article
Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein.
- Published in:
- Pharmaceutics, 2021, v. 13, n. 11, p. 1847, doi. 10.3390/pharmaceutics13111847
- By:
- Publication type:
- Article
Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution.
- Published in:
- Pharmaceutics, 2021, v. 13, n. 3, p. 430, doi. 10.3390/pharmaceutics13030430
- By:
- Publication type:
- Article
HER2-Specific Pseudomonas Exotoxin A PE25 Based Fusions: Influence of Targeting Domain on Target Binding, Toxicity, and In Vivo Biodistribution.
- Published in:
- Pharmaceutics, 2020, v. 12, n. 4, p. 391, doi. 10.3390/pharmaceutics12040391
- By:
- Publication type:
- Article
Comparative Preclinical Evaluation of Peptide-Based Chelators for the Labeling of DARPin G3 with 99m Tc for Radionuclide Imaging of HER2 Expression in Cancer.
- Published in:
- International Journal of Molecular Sciences, 2022, v. 23, n. 21, p. 13443, doi. 10.3390/ijms232113443
- By:
- Publication type:
- Article
Fusion of the mouse IgG1 Fc domain to the VHH fragment (ARP1) enhances protection in a mouse model of rotavirus.
- Published in:
- Scientific Reports, 2016, p. 30171, doi. 10.1038/srep30171
- By:
- Publication type:
- Article
Robust Expression of the Human Neonatal Fc Receptor in a Truncated Soluble Form and as a Full-Length Membrane-Bound Protein in Fusion with eGFP.
- Published in:
- PLoS ONE, 2013, v. 8, n. 11, p. 1, doi. 10.1371/journal.pone.0081350
- By:
- Publication type:
- Article
Single-step recovery and solid-phase refolding of inclusion body proteins using a polycationic purification tag.
- Published in:
- Biotechnology Journal, 2006, v. 1, n. 2, p. 187, doi. 10.1002/biot.200500023
- By:
- Publication type:
- Article
Improving the tolerance of a protein a analogue to repeated alkaline exposures using a bypass mutagenesis approach.
- Published in:
- Proteins, 2004, v. 55, n. 2, p. 407, doi. 10.1002/prot.10616
- By:
- Publication type:
- Article
Evaluation of Tc-Z-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression.
- Published in:
- Amino Acids, 2015, v. 47, n. 2, p. 303, doi. 10.1007/s00726-014-1859-z
- By:
- Publication type:
- Article
Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model.
- Published in:
- Cancers, 2021, v. 13, n. 16, p. 3939, doi. 10.3390/cancers13163939
- By:
- Publication type:
- Article
Influence of the Position and Composition of Radiometals and Radioiodine Labels on Imaging of Epcam Expression in Prostate Cancer Model Using the DARPin Ec1.
- Published in:
- Cancers, 2021, v. 13, n. 14, p. 3589, doi. 10.3390/cancers13143589
- By:
- Publication type:
- Article
Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model.
- Published in:
- Cancers, 2021, v. 13, n. 1, p. 85, doi. 10.3390/cancers13010085
- By:
- Publication type:
- Article
Incorporation of a Hydrophilic Spacer Reduces Hepatic Uptake of HER2-Targeting Affibody–DM1 Drug Conjugates.
- Published in:
- Cancers, 2019, v. 11, n. 8, p. 1168, doi. 10.3390/cancers11081168
- By:
- Publication type:
- Article
Charge engineering of a protein domain to allow efficient ion-exchange recovery.
- Published in:
- Protein Engineering, 2000, v. 13, n. 10, p. 703
- By:
- Publication type:
- Article
[Tc(CO)]-(HE)-Z, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2013, v. 40, n. 3, p. 439, doi. 10.1007/s00259-012-2284-8
- By:
- Publication type:
- Article
Selection and characterization of Affibody® ligands to the transcription factor c-Jun.
- Published in:
- Biotechnology & Applied Biochemistry, 2009, v. 52, n. 1, p. 17, doi. 10.1042/BA20070178
- By:
- Publication type:
- Article
Proof-of-Concept of Continuous Transfection for Adeno-Associated Virus Production in Microcarrier-Based Culture.
- Published in:
- Processes, 2022, v. 10, n. 3, p. 515, doi. 10.3390/pr10030515
- By:
- Publication type:
- Article
Imaging of Insulinlike Growth Factor Type 1 Receptor in Prostate Cancer Xenografts Using the Affibody Molecule <sup>111</sup>In-DOTA-Z<sub>IGF1R:4551</sub>.
- Published in:
- Journal of Nuclear Medicine, 2012, v. 53, n. 1, p. 90, doi. 10.2967/jnumed.111.090829
- By:
- Publication type:
- Article
Potent and specific fusion toxins consisting of a HER2-binding, ABD-derived affinity protein, fused to truncated versions of Pseudomonas exotoxin A.
- Published in:
- International Journal of Oncology, 2019, v. 55, n. 1, p. 309, doi. 10.3892/ijo.2019.4814
- By:
- Publication type:
- Article
Influence of molecular design on biodistribution and targeting properties of an Affibody-fused HER2-recognising anticancer toxin.
- Published in:
- International Journal of Oncology, 2016, v. 49, n. 3, p. 1185, doi. 10.3892/ijo.2016.3614
- By:
- Publication type:
- Article
Target-specific cytotoxic effects on HER2-expressing cells by the tripartite fusion toxin Z<sub>HER2:2891</sub>-ABD-PE38X8, including a targeting affibody molecule and a half-life extension domain.
- Published in:
- International Journal of Oncology, 2015, v. 47, n. 2, p. 601, doi. 10.3892/ijo.2015.3027
- By:
- Publication type:
- Article
Selection of affibody molecules to the ligand-binding site of the insulin-like growth factor-1 receptor.
- Published in:
- Biotechnology & Applied Biochemistry, 2010, v. 55, n. 2, p. 99, doi. 10.1042/ba20090226
- By:
- Publication type:
- Article
Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules.
- Published in:
- Biomedicines, 2022, v. 10, n. 6, p. 1293, doi. 10.3390/biomedicines10061293
- By:
- Publication type:
- Article
An in vivo half-life extended prolactin receptor antagonist can prevent STAT5 phosphorylation.
- Published in:
- PLoS ONE, 2019, v. 14, n. 5, p. 1, doi. 10.1371/journal.pone.0215831
- By:
- Publication type:
- Article
Preclinical Evaluation of HER2-Targeting DARPin G3: Impact of Albumin-Binding Domain (ABD) Fusion.
- Published in:
- International Journal of Molecular Sciences, 2024, v. 25, n. 8, p. 4246, doi. 10.3390/ijms25084246
- By:
- Publication type:
- Article